Actively Recruiting
Phase II Randomized Study of SAL0140 Tablets for Adults With Uncontrolled Hypertension Comparing Multiple Dose Levels
Led by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Updated on 2026-06-17
252
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the effectiveness and safety of SAL0140 at different doses in adults with uncontrolled hypertension. It is a multicenter, randomized, double-blind, placebo-controlled phase II trial designed to compare how various doses of SAL0140 affect blood pressure control in patients whose hypertension is not adequately managed. Participants are randomly assigned to one of four groups low-dose SAL0140, middle-dose SAL0140, high-dose SAL0140, or a placebo group. They receive the assigned treatment during a double-blind period, followed by a withdrawal period where the treatment is stopped to observe effects. During the study, participants undergo regular assessments including measurements of their seated systolic blood pressure at baseline and at week 12. The main outcome measured is the change in mean seated systolic blood pressure from baseline to week 12. Safety and adherence are monitored throughout, and participants involvement spans the treatment and withdrawal periods with scheduled visits for evaluation.
CONDITIONS
Brief Title
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension
Research Team
J
Jun Cai, professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here